Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study - PubMed
7 hours ago
- #Lebrikizumab
- #Atopic Dermatitis
- #Real-World Study
- Study evaluates the effectiveness of lebrikizumab in patients with atopic dermatitis who switched from dupilumab or tralokinumab over 48 weeks.
- The research was approved by the Ethics Committee of Nippon Medical School Chiba Hokusoh Hospital and Nippon Medical School (ethics approval no. R-2024-160).
- Informed consent was obtained from all participants for both participation and publication.
- Data availability upon request from the corresponding author.
- Authors contributed significantly, with Teppei Hagino leading the study organization and Naoko Kanda supervising.
- Conflicts of interest disclosed, with some authors receiving lecture fees from Eli Lilly.